Health
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial – The Lancet
This first-in-human trial shows that a subunit vaccine comprising mammalian cell culture-derived,MF59-adjuvanted, molecular clamp-stabilised recombinant spike protein…
We use cookies to help provide and enhance our service and tailor content and ads. To update your cookie settings, please visit the Cookie Preference Center for this site.Copyright © 2021 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.
Privacy Policy Terms and Conditions
-
Noosa News21 hours agoDog daycare program a TikTok hit for helping disabled find work, friends
-
Noosa News23 hours agoParkyn this, Parkyn that | Noosa Today
-
Noosa News23 hours agoR Tee in the running to be top dog
-
Noosa News20 hours agoAdvocates highlight sexual violence against older people, with Queensland elder abuse inquiry underway